SAVA — Cassava Sciences, Inc.

Summary of Cassava Sciences Q3 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2024, Cassava reported $149 million in cash, expected to sustain operations through the conclusion of ongoing Phase 3 trials and into 2026. An additional $40 million is held in restricted cash for a settlement with the SEC.
• Net Loss: The company posted a net loss of $27.9 million ($0.58 per share) for Q3 2024, compared to a net loss of $25.7 million ($0.61 per share) in Q3 2023.
• Expenses: Research and development expenses decreased to $17.7 million from $23.6 million year-over-year, while general and administrative expenses rose significantly to $12.9 million due to increased legal costs and compensation.

2. Strategic Updates and Business Highlights

• Phase 3 Trial Progress: Cassava announced the completion of the last patient/last visit for its Phase 3 trial, RETHINK-ALZ, with database cleanup ongoing. Top-line results are expected by year-end 2024.
• Biomarker Data: The company plans to report biomarker data alongside cognition data from the trial, focusing on p-tau217, neurofilament Light Chain (NfL), glial fibrillary acidic protein (GFAP), and total-tau.
• Manufacturing Expansion: Cassava is expanding its manufacturing capabilities in anticipation of potential success with simufilam, aiming to provide a treatment option that could be prescribed by primary care physicians.

3. Forward Guidance and Outlook

• Operational Cash Guidance: The company expects to end 2024 with between $117 million to $127 million in cash, consistent with previous guidance.
• Market Potential: If successful, simufilam could provide a disease-modifying treatment option for the approximately 7 million diagnosed Alzheimer's patients in the U.S., with a focus on improving early diagnosis and treatment by primary care physicians.

4. Bad News, Challenges, or Points of Concern

• Legal and Regulatory Scrutiny: The company is under scrutiny due to a settlement with the SEC, which could impact its operations and financial position.
• Clinical Trial Risks: The success of the Phase 3 trial is uncertain, with the need to meet both primary endpoints (ADAS-Cog12 and activities of daily living) for regulatory approval. There are concerns about potential underperformance in moderate patients affecting overall trial success.
• Resource Allocation: Cassava faces challenges in resource allocation for future indications of simufilam, given its limited size and the need to prioritize between diagnostics and other therapeutic indications.

5. Notable Q&A Insights

• SavaDx Status: There is uncertainty regarding the future of the SavaDx diagnostic tool in light of advancements in existing biomarker diagnostics, with management indicating a need to evaluate resource allocation post-trial results.
• Statistical Analysis Plan: The statistical analysis plan has been finalized and submitted to the FDA, with both primary endpoints needing to be met for trial success.
• Market Entry Timeline: If successful, simufilam could potentially reach the market in late summer to early fall of 2026.
• Future Indications: Management hinted at exploring other indications for simufilam, particularly in conditions like Tuberous Sclerosis, which could be pursued with fewer resources and quicker timelines.

Overall, Cassava Sciences is at a critical juncture with its Phase 3 Alzheimer's trial results imminent, while navigating financial and operational challenges amidst a competitive landscape.